Loading…
Yantai-based maker of iodine contrast media and radiopharmaceuticals used in medical imaging and nuclear medicine.
Yantai-based maker of iodine contrast media and radiopharmaceuticals used in medical imaging and nuclear medicine.
In one line: A small Chinese GE Healthcare contrast-agent unit.
Moat: narrow (regulatory licence, distribution). Licensed isotope handling and a national contrast-agent distribution network are hard to replicate.
Headquarters: Yantai, China · Employees: 2,583
Size Yantai Dongcheng Biochemicals (002675.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.67B, the 1484th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥13.18 on 6 Nov 2026.
Performance Over six months the shares gained 1.5%, against -4.8% for the median peer and -16.4% for the China market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue fell 4.2% over the last twelve months (peer median +15.7%); the operating margin is 14.8% (peer median 13.0%).
Valuation It trades at 47.5× forward earnings against a peer median of 27.8× (4th most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.4 points above its cost of capital (5.0% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.63B | CN¥2.72B | CN¥2.85B | CN¥3.26B | CN¥3.57B |
| Revenue growth | — | -5% | -12% | -9% | — |
| Gross profit | CN¥1.50B | CN¥1.30B | CN¥1.26B | CN¥1.40B | CN¥1.48B |
| EBITDA | n/a | CN¥572M | CN¥456M | CN¥529M | CN¥680M |
| Net income | CN¥210M | CN¥196M | CN¥184M | CN¥210M | CN¥307M |
| Free cash flow | CN¥112M | CN¥224M | -CN¥163M | -CN¥203M | CN¥615M |
| Capital expenditure | CN¥388M | CN¥361M | CN¥456M | CN¥512M | CN¥390M |
| Total debt | CN¥1.49B | CN¥2.61B | CN¥2.26B | CN¥1.72B | CN¥1.84B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Yantai Dongcheng Biochemicals 002675.SZ | $1.67B | +1% | -4% | 15% | 47.5× | 6.7% |
| GE HealthCare GEHC | $37.2B | +30% | +7% | 14% | 15.4× | 4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002675.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.3% | -1.0% | 8th highest of 21 |
| 6-month return | +1.5% | -4.8% | 8th highest of 20 |
| Distance from 52-week high | -18.3% | -34.5% | 6th highest of 21 |
| Revenue growth (TTM) | -4.2% | +15.7% | 6th lowest of 19 |
| Operating margin | 14.8% | 13.0% | 9th highest of 19 |
| Forward P/E | 47.5× | 27.8× | 4th most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 6.7% | 8.9% | 7th least demanding of 13 |
| Growth delivered (Del g) | -4.3% | +12.1% | 3rd lowest of 13 |
| Hurdle (Req g minus delivered) | +11.0 pp | -4.0 pp | 4th most demanding of 13 |
| ROIC minus cost of capital | +1.4 pp | +1.7 pp | 9th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.67B | +1% | -4% | 15% | 47.5× | 6.7% | -4.3% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| NATCO Pharma NATCOPHARM.NS | India | $1.68B | -30% | -21% | 25% | 18.8× | 15.3% | +19.0% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.67B | -14% | -13% | 6% | 13.2× | -6.0% | -5.6% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.69B | -25% | +31% | 10% | n/a | 49.3% | +23.0% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 9.2× | -15.1% | +13.5% |
| SELLAS Life Sciences SLS | United States | $1.70B | +68% | n/a | n/a | n/a | n/a | n/a |
| Faes Farma FAE.MC | Spain | $1.71B | +5% | +32% | 14% | 17.1× | 3.1% | +9.9% |
| Yifan Pharmaceutical 002019.SZ | China | $1.72B | -14% | -5% | 8% | 27.8× | n/a | n/a |
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 16.2× | -4.5% | +6.8% |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 27.9× | 39.6% | +359.6% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | n/a | -4.1% | +0.2% |
| Cohance Lifesciences COHANCE.NS | India | $1.75B | -11% | +41% | 6% | 82.6× | n/a | n/a |
| Agios Pharmaceuticals AGIO | United States | $1.76B | +6% | +141% | -467% | n/a | n/a | n/a |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.76B | -25% | -13% | 12% | 63.3× | 14.7% | -14.0% |
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | n/a | n/a | n/a |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.58B | -4% | +16% | 9% | 29.0× | n/a | n/a |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.77B | -11% | +7% | 39% | 27.8× | 19.5% | +10.8% |
| Xiamen Kingdomway 002626.SZ | China | $1.58B | +15% | -3% | 11% | 30.0× | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.58B | +40% | +17% | 18% | 63.7× | 37.6% | +16.6% |
| PharmaResearch 214450.KS | South Korea | $1.79B | -25% | +34% | 39% | 12.4× | -14.2% | +37.6% |